

Alport Syndrome - Pipeline Review - 2019

<https://marketpublishers.com/r/AD78BDA2ECB8EN.html>

Date: December 2019

Pages: 130

Price: US\$ 1,250.00 (Single User License)

ID: AD78BDA2ECB8EN

Abstracts

Firstview Insight's Alport Syndrome - Pipeline Review-2019 provides an overview of the pipeline landscape of Alport Syndrome. It provides comprehensive insights of all the clinical and non-clinical therapeutics in development with detailed description about the collaborations; deals; designations; patent information etc. These reports encourage the clients in distinguishing the upcoming and existing competitors in their separate therapeutic spaces. The report provides detailed description of the competitor profiles with key milestones and evidence along with analysis by mechanism of action; route of administration; molecule type; stage of development. Information obtained from multiple sources will be used to triangulate and update the profiles. The report also provides key events in the last year related to the indication. This report provides detailed analysis of all the products along with the companies involved.

Alport syndrome is a genetic condition characterized by kidney disease, hearing loss, and eye abnormalities. Most affected individuals experience progressive loss of kidney function, usually resulting in end-stage kidney disease. People with Alport syndrome also frequently develop sensorineural hearing loss in late childhood or early adolescence. The eye abnormalities characteristic of this condition seldom lead to vision loss. In 80% of cases, Alport syndrome is inherited in an X-linked manner and is caused by mutations in the COL4A5 gene. In the remaining cases, it may be inherited in either an autosomal recessive, or rarely in an autosomal dominant manner. In these cases, the condition is caused by mutations in the COL4A3 or COL4A4 genes.

There are three genetic types of Alport syndrome.

X-linked Alport syndrome (XLAS)

Autosomal recessive Alport syndrome (ARAS)

Autosomal dominant Alport syndrome (ADAS)

Currently, there is no specific treatment for Alport syndrome. The goal is to treat the

symptoms and help slow the progression of kidney disease. This may include:

ACE inhibitor or ARB medicines (medications to control high blood pressure)

Diuretics (water pills)

Limit sodium (salt) in your diet

Report covers ~20 drugs Drug Profile Overview:

The pipeline section provides descriptive drug profiles for the pipeline products including product description, mechanism of action, route of administration, molecule type, technology involved, chemical information.

Clinical Trial Overview:

This section of the report focuses on the clinical activity of the molecule. It includes both clinical and pre-clinical activity which provides detailed information about the safety, efficacy, tolerability, toxicity of pipeline drugs. A graphical representation of the clinical trial landscape of pipeline therapy which includes information about phase of development, trial design, treatment arms, dosage and frequency, formulation of the drug, primary and secondary completion date, enrolment number, exclusion and inclusion criteria, line of therapy. This section also includes the clinical trial results and analysis based on those results.

Product Development Activity:

This section of the report focuses on detail information about designations, exclusivity details, technology, licensing and collaboration, funding and financing, key milestones and various other development activities.

Company Overview:

Company profile includes the detail about type of company, headquarter, global presence, research focus and key financial

Scope

The report provides a competitive landscape

The report also provides clinical trial landscape of the pipeline drugs including

status; trial phase; sponsor type and end-point status

The report provides the list of companies which are the most active in the pipeline

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery

The report provides descriptive drug profiles which includes product description; comprising detailed mechanism of action (MoA); route of administration (RoA); Stage of development; clinical trial status; licensing and collaboration details & other developmental activities

The report features comparative analysis of product profiles based on molecule type; mechanism of action (MoA); route of administration (RoA)

The report summarizes all the dormant and discontinued pipeline projects

The report also provides latest news for the past one year

Reasons To Buy

To identifying prominent players in the treatment landscape

To determine the drivers; barriers and unmet need in the treatment space

Gain strategically significant competitor information; analysis; and insights to formulate effective R&D strategies

Define in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

To understand the composition of the pipeline in terms of molecule type; molecular target; mechanism of action and route of administration

List of products

Hydroxypropyl betadex

Lademirsen

Bardoxolone methyl

eptotermin alfa

Lademirsen

Contents

1. DISEASE OVERVIEW

- 1.1. Pathophysiology
- 1.2. Symptoms
- 1.3. Etiology
- 1.4. Diagnosis
- 1.5. Etiology
- 1.6. Treatment Algorithm
- 1.7. Treatment Options

2. FEATURED NEWS AND PRESS RELEASES, 2018-2028

3. LIST OF COMPANIES DEVELOPING PRODUCTS FOR ALPORT SYNDROME

4. TREATMENT ALGORITHM

5. CURRENT UNMET NEEDS

6. MARKET TRENDS

7. PIPELINE THERAPEUTICS

8. THERAPEUTICS UNDER DEVELOPMENT BY COMPANIES

9. LATE STAGE PRODUCTS (PHASE III)

9.1 Drug 1

- 9.1.1. Product Description
- 9.1.2. Research and Development
- 9.1.3. Product Development Activities

9.2. Drug 2

- 9.2.1. Product Description
- 9.2.2. Research and Development
- 9.2.3. Product Development Activities

10. MID STAGE PRODUCTS (PHASE II)

10.1 Drug 1

- 10.1.1. Product Description
- 10.1.2. Research and Development
- 10.1.3. Product Development Activities

10.2. Drug 2

- 10.2.1. Product Description
- 10.2.2. Research and Development
- 10.2.3. Product Development Activities

11. EARLY STAGE AND PRECLINICAL PRODUCTS (PHASE II)

11.1 Drug 1

- 11.1.1. Product Description
- 11.1.2. Research and Development
- 11.1.3. Product Development Activities

11.2. Drug 2

- 11.2.1. Product Description
- 11.2.2. Research and Development
- 11.2.3. Product Development Activities

12. DRIVERS OF ALPORT SYNDROME

13. CONSTRAINTS OF ALPORT SYNDROME

14. THERAPEUTIC ASSESSMENT

- 14.1. Assessment by Route of Administration
- 14.2. Assessment by Phase & Route of Administration
- 14.3. Assessment by Molecule Type
- 14.4. Assessment by Phase & Molecule type
- 14.5. Assessment by Target
- 14.6. Assessment by Mechanism of Action

15. COLLABORATIONS AND ACQUISITIONS DETAILS

16. DORMANT PRODUCTS

17. DISCONTINUED PRODUCTS

18. MARKET TRENDS

19. MARKET OPPORTUNITY ASSESSMENT

20. UNMET NEEDS

21. SWOT ANALYSIS

22. APPENDIX

23. REPORT METHODOLOGY

24. CONSULTING SERVICES

25. DISCLAIMER

List Of Tables

LIST OF TABLES

Table 1: Marketed Alport Syndrome drugs, 2019

Table 2: Sales of Marketed drugs

Table 3: Patent expiration details – marketed drugs

Table 4: Number of Products Under Development for Alport Syndrome

Table 5: Products under Development by Companies

Table 6: Late Stage Products

Table 7: Mid Stage Products

Table 8: Early Stage Products

Table 9: Pre-Clinical and Discovery Products

Table 10: Assessment by Route of Administration

Table 11: Assessment by Stage and Route of Administration

Table 12: Assessment by Molecule Type

Table 13: Assessment by Stage and Molecule Type

Table 14: Assessment by Target

Table 15: Assessment by Mechanism of Action

Table 16: Dormant Products

Table 17: Discontinued Products

List Of Figures

LIST OF FIGURES

- Figure 1: Marketed and Pipeline Alport Syndrome drugs, 2019
- Figure 2: Sales of Marketed drugs
- Figure 3: Patent expiration details – marketed drugs
- Figure 4: Number of Products Under Development for Alport Syndrome
- Figure 5: Products under Development by Companies
- Figure 6: Late Stage Products
- Figure 7: Mid Stage Products
- Figure 8: Early Stage Products
- Figure 9: Pre-Clinical and Discovery Products
- Figure 10: Assessment by Route of Administration
- Figure 11: Assessment by Stage and Route of Administration
- Figure 12: Assessment by Molecule Type
- Figure 13: Assessment by Stage and Molecule Type
- Figure 14: Assessment by Target
- Figure 15: Assessment by Mechanism of Action
- Figure 16: Dormant Products
- Figure 17: Discontinued Products

I would like to order

Product name: Alport Syndrome - Pipeline Review - 2019

Product link: <https://marketpublishers.com/r/AD78BDA2ECB8EN.html>

Price: US\$ 1,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/AD78BDA2ECB8EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970